Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aileron Therapeutics, Inc. stock logo
ALRN
Aileron Therapeutics
$2.52
$1.61
$4.40
$45.72M2.2479,635 shs63,385 shs
Check-Cap Ltd. stock logo
CHEK
Check-Cap
$0.82
-0.5%
$0.76
$0.56
$3.04
$4.77M0.21370,174 shs125,238 shs
Dynatronics Co. stock logo
DYNT
Dynatronics
$0.10
-2.5%
$0.10
$0.08
$0.48
$1.04M0.457,581 shs581 shs
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
$0.38
$0.38
$0.36
$4.80
$1.43MN/AN/AN/A
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aileron Therapeutics, Inc. stock logo
ALRN
Aileron Therapeutics
0.00%0.00%0.00%0.00%-44.76%
Check-Cap Ltd. stock logo
CHEK
Check-Cap
0.00%+3.06%+21.29%-8.98%-62.59%
Dynatronics Co. stock logo
DYNT
Dynatronics
0.00%+23.30%-15.25%-20.63%-78.84%
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
0.00%0.00%0.00%0.00%+0.53%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aileron Therapeutics, Inc. stock logo
ALRN
Aileron Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Check-Cap Ltd. stock logo
CHEK
Check-Cap
0.9902 of 5 stars
0.05.00.00.02.70.00.6
Dynatronics Co. stock logo
DYNT
Dynatronics
N/AN/AN/AN/AN/AN/AN/AN/A
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aileron Therapeutics, Inc. stock logo
ALRN
Aileron Therapeutics
4.00
Strong BuyN/AN/A
Check-Cap Ltd. stock logo
CHEK
Check-Cap
0.00
N/AN/AN/A
Dynatronics Co. stock logo
DYNT
Dynatronics
0.00
N/AN/AN/A
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aileron Therapeutics, Inc. stock logo
ALRN
Aileron Therapeutics
N/AN/AN/AN/A$1.41 per shareN/A
Check-Cap Ltd. stock logo
CHEK
Check-Cap
N/AN/AN/AN/A$4.05 per shareN/A
Dynatronics Co. stock logo
DYNT
Dynatronics
$33.60M0.03N/AN/A$0.57 per share0.17
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aileron Therapeutics, Inc. stock logo
ALRN
Aileron Therapeutics
-$15.73M-$3.120.00N/AN/AN/A-74.08%-27.93%N/A
Check-Cap Ltd. stock logo
CHEK
Check-Cap
-$17.57M-$3.00N/AN/AN/AN/AN/A5/13/2025 (Estimated)
Dynatronics Co. stock logo
DYNT
Dynatronics
-$2.70M-$0.82N/AN/A-8.35%-41.81%-9.56%5/12/2025 (Estimated)
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
-$4.37MN/A0.00N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aileron Therapeutics, Inc. stock logo
ALRN
Aileron Therapeutics
N/AN/AN/AN/AN/A
Check-Cap Ltd. stock logo
CHEK
Check-Cap
N/AN/AN/AN/AN/A
Dynatronics Co. stock logo
DYNT
Dynatronics
N/AN/AN/AN/AN/A
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aileron Therapeutics, Inc. stock logo
ALRN
Aileron Therapeutics
N/A
3.30
3.30
Check-Cap Ltd. stock logo
CHEK
Check-Cap
N/A
19.67
N/A
Dynatronics Co. stock logo
DYNT
Dynatronics
0.25
1.21
0.60
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Aileron Therapeutics, Inc. stock logo
ALRN
Aileron Therapeutics
90.89%
Check-Cap Ltd. stock logo
CHEK
Check-Cap
1.07%
Dynatronics Co. stock logo
DYNT
Dynatronics
4.18%
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
12.37%

Insider Ownership

CompanyInsider Ownership
Aileron Therapeutics, Inc. stock logo
ALRN
Aileron Therapeutics
5.10%
Check-Cap Ltd. stock logo
CHEK
Check-Cap
0.48%
Dynatronics Co. stock logo
DYNT
Dynatronics
7.98%
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
7.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aileron Therapeutics, Inc. stock logo
ALRN
Aileron Therapeutics
921.67 million20.56 millionNot Optionable
Check-Cap Ltd. stock logo
CHEK
Check-Cap
805.85 million5.82 millionNot Optionable
Dynatronics Co. stock logo
DYNT
Dynatronics
20010.62 million8.11 millionNot Optionable
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
403.75 million3.46 millionNot Optionable

Recent News About These Companies

Greenlight Capital Q3 2024 Letter
NeuBase Therapeutics Inc
NeuBase Therapeutics, Inc. (NBSE)
NeuBase Therapeutics Inc (O7P.BE)
CMU halts licensing agreement with NeuBase Therapeutics
NeuBase Therapeutics Inc NBSE
NeuBase Therapeutics: Other Events
NeuBase Therapeutics, Inc. (NBSE.MX)

Media Sentiment Over Time

Aileron Therapeutics stock logo

Aileron Therapeutics NASDAQ:ALRN

Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas.

Check-Cap stock logo

Check-Cap NASDAQ:CHEK

$0.82 0.00 (-0.52%)
Closing price 03:55 PM Eastern
Extended Trading
$0.88 +0.07 (+8.59%)
As of 06:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. Check-Cap Ltd. was incorporated in 2004 and is based in Isfiya, Israel.

Dynatronics stock logo

Dynatronics NASDAQ:DYNT

$0.10 0.00 (-2.50%)
As of 03:36 PM Eastern

Dynatronics Corporation, a medical device company, designs, manufactures, and sells physical therapy, rehabilitation, orthopedics, pain management, and athletic training products in the United States. The company offers orthopedic soft bracing products include cervical collars, shoulder immobilizers, arm slings, wrist and elbow supports, abdominal and lumbosacral supports, maternity supports, knee immobilizers and supports, ankle walkers and supports, plantar fasciitis splints, and cold therapy products. It also offers physical therapy and rehabilitation products, which include therapeutic modality devices comprising electrotherapy, ultrasound, phototherapy, traction, hot and cold therapy, and electrodes; and power and manually operated treatment tables, mat platforms, work tables, parallel bars, training stairs, weight racks, and other related equipment. In addition, the company manufactures and distributes clinical supplies, including exercise bands and tubing, lotions and gels, orthopedic bracings, paper products, and other related supplies. It markets its products under the Dynatron, Dynatron Solaris, Dynaheat, BodyIce, Powermatic, Bird & Cronin, Physician's Choice, Hausmann, PROTEAM, and Mammoth brands. The company sells its products to orthopedists, physical therapists, chiropractors, athletic trainers, sports medicine practitioners, clinics, hospitals, and retail distributors and equipment manufacturers. It also exports its products in Asia, Latin America, and the Middle East. Dynatronics Corporation was founded in 1979 and is headquartered in Eagan, Minnesota.

NeuBase Therapeutics stock logo

NeuBase Therapeutics NASDAQ:NBSE

NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.